← Back to Clinical Trials
Recruiting NCT07424638

NCT07424638 Interscalene Block Versus Anterior Suprascapular Block for Post-Thoracotomy Shoulder Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07424638
Status Recruiting
Phase
Sponsor National Cancer Institute, Egypt
Condition Interscalene Block
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2026-02-21
Primary Completion 2026-07-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Interscalene blockAnterior suprascapular blockEpidural analgesia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2026-02-21 with a primary completion date of 2026-07-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the frequency of occurrence of ipsilateral shoulder pain in patients undergoing thoracotomy with ultrasound-guided interscalene block, anterior suprascapular block as adjunct to epidural and epidural block only.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years and ≤ 65 years old. * American Society of Anesthesiologists (ASA) physical status II-III. * Body mass index 18-35 kg/m2. * Patients who have a confirmed diagnosis of lung cancer and are scheduled for elective open-lung surgery. Exclusion Criteria: * Allergy to local anesthetics. * Known psychiatric or neurologic disorders. * Alcohol or narcotics abuse. * Contraindications to thoracic epidural or suprascapular block, or interscalene block, e.g., coagulopathy or local infection. * Pre-existing shoulder symptoms. * History of previous thoracotomy. * Severe restrictive or obstructive pulmonary disease. * Pre-existing contralateral diaphragmatic paralysis.

Contact & Investigator

Central Contact

Mai M Elrawas, MD

✉ mai.elrawas@nci.cu.edu.eg

📞 00201222177242

Frequently Asked Questions

Who can join the NCT07424638 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Interscalene Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07424638 currently recruiting?

Yes, NCT07424638 is actively recruiting participants. Contact the research team at mai.elrawas@nci.cu.edu.eg for enrollment information.

Where is the NCT07424638 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07424638 clinical trial?

NCT07424638 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology